

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Zylox-Tonbridge Medical Technology Co., Ltd.

歸創通橋醫療科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2190)

VOLUNTARY ANNOUNCEMENT

Completion of Patient Enrollment for the Clinical Trial of Zynlastic® Peripheral Venous Stent System

This announcement is made by Zylox-Tonbridge Medical Technology Co., Ltd. (the “**Company**”, together with its subsidiary, the “**Group**”) on a voluntary basis to provide the shareholders and potential investors with updated information in relation to the latest business and new product development of the Group.

The Company is pleased to announce that by July 12, 2021, the Company has completed the patient enrollment process for the clinical trial of Zynlastic® Peripheral Venous Stent System (“**Zynlastic®**”), a major product candidate in the Company’s peripheral vascular product portfolio. Our peripheral venous stent system is designed for the treatment of iliac vein stenosis or occlusive disease such as iliac vein compression syndrome (“**IVCS**”).

The Company plans to make the registration submission for Zynlastic® with National Medical Products Administration (“**NMPA**”) in early fourth quarter of 2022 after 12-month follow-up, which is approximately six months ahead of the schedule previously disclosed in the prospectus of the Company dated June 22, 2021 (i.e. the second quarter of 2023), and expects to receive NMPA approval for Zynlastic® in 2023.

THE COMPANY MAY NOT BE ABLE TO ULTIMATELY DEVELOP AND MARKET ZYNLASTIC® PERIPHERAL VENOUS STENT SYSTEM SUCCESSFULLY. SHAREHOLDERS AND POTENTIAL INVESTORS OF THE COMPANY ARE ADVISED TO EXERCISE CAUTION WHEN DEALING IN THE SHARES OF THE COMPANY.

By order of the board of directors
Zylox-Tonbridge Medical Technology Co., Ltd.
Dr. Jonathon Zhong Zhao
Chairman and Executive Director

Hong Kong, July 12, 2021

As of the date of this announcement, the board of directors of the Company comprises Dr. Jonathon Zhong Zhao, Mr. Yang Xie and Dr. Zheng Li as executive directors, Mr. Stephen Hui Wang, Dr. Hai Lu and Dr. Steven Dasong Wang as non-executive directors, and Dr. Jian Ji., Mr. Hongze Liang and Ms. Yun Qiu as independent non-executive directors.